BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Expanded Access for Abatacept
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05170672
- Locations
- ๐บ๐ธ
Local Institution - 0001, Austin, Texas, United States
๐ง๐ชLocal Institution - 0002, Leuven, Vlaams-brabant, Belgium
Expanded Access for Relatlimab
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05170659
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT05169684
- Locations
- ๐บ๐ธ
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
๐จ๐ฆLocal Institution - 0028, Toronto, Ontario, Canada
๐บ๐ธThe Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1182
- Registration Number
- NCT05170126
- Locations
- ๐บ๐ธ
ZEPOSIA MS Pregnancy Registry, Wilmington, North Carolina, United States
๐ฉ๐ชMarienhospital Herne, Klinikum Der Ruhr-Universitaet Bochum, Herne, Germany
A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 105
- Registration Number
- NCT05168436
- Locations
- ๐ช๐ธ
Local Institution, Castellon de La Plana, Spain
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 218
- Registration Number
- NCT05168202
- Locations
- ๐บ๐ธ
Local Institution - 0001, Houston, Texas, United States
๐ฆ๐บLocal Institution - 0027, Wollongong, New South Wales, Australia
๐ฆ๐บLocal Institution - 0006, Clayton, Victoria, Australia
A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer
- Conditions
- Gastric Cancer
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT05165264
- Locations
- ๐ฉ๐ช
Local Institution - 0001, Hamburg, Germany
A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 525
- Registration Number
- NCT05161325
- Locations
- ๐ฏ๐ต
Local Institution, Minato-ku, Tokyo, Japan
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT05162222
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
- Conditions
- Mesothelioma, Malignant
- Interventions
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT05136677
- Locations
- ๐จ๐ณ
The First Affiliated Hospital of Zhengzhou Universtiy-Oncology department, Zhengzhou, Henan, China
๐จ๐ณLocal Institution - 0012, Ningbo, Zhejiang, China
๐จ๐ณBeijing Cancer hospital-Thoracic Cancer Department A, Beijing, Beijing, China